The interaction of delta9-tetrahydrocannabinol with cholinomimetic drugs in an agonist-antagonist paradigm.
In rabbits, i.v. delta9-tetrahydrocannabinol (delta9-THC) at 0.5 mg/kg was challenged with i.v. arecoline (0.025 mg/kg), nicotine (0.02 mg/kg) or physostigmine (PHYSO, 0.05 mg/kg), and observations were made on quantified EEG and behavior. The cholinomimetics effectively reversed the cortical and hippocampal EEG alterations induced by delta9-THC. Arecoline and PHYSO temporarily reversed the behavioral-sedative effects of delta9-THC whereas the combination of delta9-THC with nicotine produced behavioral collapse preceded by behavioral disturbance.
D000818:Animals; D001115:Arecoline / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects; D002188:Cannabis / Q000494:pharmacology*; D013759:Dronabinol / Q000494:pharmacology*; D004347:Drug Interactions; D004567:Electrodes, Implanted; D004569:Electroencephalography; D005106:Exploratory Behavior / Q000187:drug effects; D009538:Nicotine / Q000494:pharmacology; D010277:Parasympathomimetics / Q000494:pharmacology*; D010830:Physostigmine / Q000494:pharmacology; D011187:Posture; D011817:Rabbits
D010277:Parasympathomimetics; D001115:Arecoline; D009538:Nicotine; D013759:Dronabinol; D010830:Physostigmine